ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ...
Total Revenue: $8 million for Q1 2025.
US Net Product Revenue for neffy: $7.8 million.
Collaboration Revenue: $0.2 million from ALK agreement.
Cost of Goods Sold: $1.1 million for Q1 2025.
R&D Expenses: $3 million for Q1 2025.
SG&A Expenses: $41.1 million for Q1 2025.
Planned DTC Campaign Investment: $40 million to $50 million for the remainder of 2025.
Projected 2025 Operating Expenses: $210 million to $220 million, excluding stock-based compensation and COGS.
Net Loss: $33.9 million, or $0.35 per share, for Q1 2025.
Cash, Cash Equivalents, and Short-term Investments: $275.7 million as of March 31, 2025.
Warning! GuruFocus has detected 4 Warning Signs with SPRY.
Release Date: May 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) successfully launched neffy, the first needle-free epinephrine treatment, with $7.8 million in US net product revenue in Q1 2025.
The company expanded commercial insurance coverage for neffy from 27% to 57%, with ongoing payer discussions to further increase coverage.
Neffy 1-milligram dose was approved by the FDA for children, representing a significant portion of the pediatric market.
A strategic collaboration with ALK-Abello expanded ARS Pharmaceuticals Inc (NASDAQ:SPRY)'s promotional network to over 20,000 healthcare providers, including 9,000 pediatricians.
The company is launching a comprehensive direct-to-consumer campaign to increase patient awareness and drive prescription growth for neffy.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) reported a net loss of $33.9 million for Q1 2025, indicating financial challenges despite revenue growth.
The cost of goods sold is expected to increase as the company uses up its zero-cost inventory.
Prior authorization requirements remain a barrier for some patients, with only 57% of commercial lives having access to neffy without prior authorization.
The company anticipates significant operating expenses of $210 million to $220 million for 2025, driven by marketing and commercialization efforts.
Market share for neffy is currently low at 1.3% overall, though higher among targeted high-prescribing physicians.
Q: How much of the first-quarter sales figure is attributed to inventory, and what are your expectations for inventory contribution over the next two quarters? A: Richard Lowenthal, President and CEO, stated that the first-quarter numbers were minimally influenced by inventory. The sales were primarily from 2-milligram doses, and inventory levels are steady. They do not expect inventory to significantly impact sales in the upcoming quarters.
Q: What is the current gross-to-net discount, and how has it changed from the fourth quarter to the first quarter? A: Kathleen Scott, CFO, explained that the gross-to-net discount was higher in Q4 than in Q1. With increasing insurance coverage, the gross-to-net is expected to decrease to around 50% as the year progresses.
Q: What do you expect the cost of goods sold (COGS) to be once the current inventory is used up? A: Kathleen Scott noted that some inventory was expensed prior to FDA approval, which currently benefits COGS. As this inventory is used, COGS will increase slightly, but the zero-cost inventory primarily involves raw materials, with manufacturing costs still being incurred.
Q: Can you discuss the impact of the neffy Experience Program on physician adoption and any feedback received? A: Richard Lowenthal highlighted that the neffy Experience Program has been successful, with over 2,500 physicians enrolled. Feedback has been positive, with results similar to injections, where about 90% of patients respond to a single dose. Plans are in place to expand the program and potentially publish the results.
Q: How are you tracking against your goal of 80% commercial insurance coverage by the third quarter? A: Richard Lowenthal mentioned ongoing negotiations with major insurers like Caremark and Aetna. Currently, 57% of patients have coverage without prior authorization, and efforts are underway to increase this percentage to meet the 80% goal.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Dr. Martens' Stock Soars as CEO Implements New Strategic Plan Following ‘Year of Stabilization'
Shares for Dr. Martens Plc surged nearly 24 percent on Thursday following the release of a new strategic turnaround plan in efforts to return to profit growth in fiscal 2026. According to chief executive officer Ije Nwokorie, who took the helm earlier this year, the company's 'single focus' in fiscal 2025 was to bring stability back to Dr. Martens. More from WWD Journeys Helps Genesco Deliver Q1 Sales Above Expectations Dr. Martens Looks to Adidas For New Chief Brand Officer Name Game: Shoe Carnival Is Converting More Stores to Shoe Station Banner 'We have achieved this by returning our direct-to-consumer channel in the Americas back to growth, resetting our marketing approach to focus relentlessly on our products, delivering cost savings, and significantly strengthening our balance sheet,' Nwokorie said in a statement. In fiscal 2025, the UK-based footwear company reported that net revenue fell 10 percent to 787.6 million pounds from 877.1 million in fiscal 2024. Dr. Martens noted that the results were in-line with guidance, however, and came up against a challenging macroeconomic and consumer backdrop in several of its core markets. Net debt for the year was 249.5 million pounds, down from 359.8 million pounds in fiscal 2024. Net profit stood at 4.5 million pounds in the year to the end of March, down from 69.2 million pounds the year prior. By category, overall, pairs were down 9 percent, with DTC pairs flat and wholesale pairs down 15 percent as expected, as the company's wholesale partners normalized their inventory levels. 'We saw a very strong performance in shoes, with DTC pairs up 15 percent with particular success in our bestselling Adrian loafer, as well as in new shoe families, the Lowell and Buzz,' the company said in its latest earnings statement. 'Sandals also saw a good performance, with DTC pairs up 7 percent, and we continue to see a strong performance in our mules range, led by the Zebzag. Boots remained challenging, with DTC pairs down 9 percent, with our continuity boots weaker, as expected. This was partially offset by success in product newness, both as extensions of the core icons, for example through the Ambassador soft leather boot and through new product lines such as the Anistone biker boot.' As a proportion of fiscal year 2025 Group revenue, boots accounted for 57 percent, shoes 26 percent, sandals 12 percent and bags & other 5 percent. By channel, direct-to-consumer revenue was down 4.2 percent to 510.7 million pounds in fiscal 2025, while wholesale fell 19.5 percent to 276.9 million pounds, as expected. Within DTC, retail revenue was down 5.6 percent to 242.4 million pounds and e-commerce was down 2.9 percent to 268.3 million pounds. By region, EMEA revenue was down 11.0 percent to 384.2 million pounds for the year, which was driven by the UK. In the Americas, revenue was down 11.4 percent to 288.5 million pounds, and in APAC, revenue dipped 3.8 percent to 114.9 million pounds, with a good performance in Japan and China, the company noted. Looking closer at the Americas, Dr. Martens stated that the region delivered DTC growth in the second half of fiscal 2025 as the company pivoted its marketing to 'relentlessly focus' on product. 'With new products such as Ambassador, Anistone, Buzz and Dunnet Flower performing very strongly for us and our partners; we delivered 25 million pounds of annualized cost savings, at the top end of our target, with the full benefit in fiscal 2026; and we strengthened our balance sheet through a significant reduction in inventory and net debt, as well as the successful refinancing of the Group,' the company said. As for tariffs, the company noted that the entirety of its spring/summer 2025 stock is already in the market, and by the start of July, the majority of autumn/winter 2025 will be either in the market or in transit. 'We generate strong product gross margins, which is helpful given that tariffs are charged on cost, not retail price,' the company stated. 'We will continue to assess the situation carefully, but can confirm that for SS25 and AW25 we will be keeping average prices unchanged in the market. More broadly, we continue to manage all costs tightly, working closely with our wholesale and supplier partners.' The company also released a new strategic plan on Thursday. Dubbed 'Levers For Growth,' Dr. Martens said that the plan builds on the work undertaken in fiscal 2025 to stabilize the business. The new plan focuses on four 'levers' including engaging more consumers, driving more product purchase occasions, curating market-right distribution, and simplifying the operating model. Dr. Martens said that the new strategy capitalizes on the strengths of its business, including its 'iconic global brand, high quality products, world-class supply chain, modern technology systems, committed wholesale and distributor partners and passionate and talented team,' and taps into the significant new markets and profit pools that are available to the company. Over the medium-term, Dr. Martens said it expects to deliver sustainable, profitable revenue growth above the rate of the relevant footwear market, with operating leverage driving a mid to high-teens EBIT margin and underpinned by strong cash generation. 'Levers For Growth will increase our opportunities by shifting the business from a channel-first to a consumer-first mindset,' Nwokorie said. 'We will give more people more reasons to buy more of our products, whether that's our iconic boots and shoes, newer product families such as Zebzag and Buzz, or adjacent categories such as sandals, bags and leather goods. And we will tailor distribution to each market, blending DTC and B2B, optimizing brand reach and ensuring a better use of capital.' The CEO added that he is 'laser focused' on day-to-day execution, managing costs and maintaining the company's operational discipline while it navigates the current macroeconomic uncertainties. Best of WWD All the Retailers That Nike Left and Then Went Back Mikey Madison's Elegant Red Carpet Shoe Style [PHOTOS] Julia Fox's Sleekest and Boldest Shoe Looks Over the Years [Photos] Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Nectar Social buzzes out of stealth with $10.6 million backing from GV and True Ventures
Going viral isn't luck. 'A book that I'll write one day is going to be called 'Manufacturing Virality,'' said Misbah Uraizee. 'It absolutely is manufacturable, and there's a playbook.' That playbook includes selective engagement, showing up in search, and partnerships with micro-influencers—not celebrities. It means seeding content, hosting real-life events, and using tools like polls and DMs to spark interaction. The goal: Build a community that talks, tags, and buys. Because even if virality can be engineered, it still has to come from somewhere real. 'For all of our customers, organic communities are the hardest,' said Uraizee. 'You've got paid metrics, you can buy more reach, you're able to scale at a certain length. But your organic traction—your organic community and how you show up there—is really the most authentic representation of your brand, and how viral or how much traction it has.' Misbah and her sister Farah Uraizee, both former Meta leaders—Misbah in product, Farah in engineering—left in 2023 to cofound Nectar Social, an agentic AI social commerce startup. Translation: The startup is looking to channel the social activity jungle into quantifiable revenue for brands. 'We saw how much private messaging was blowing up, and how terrible the internal elements were for brands to process and scale to that,' said Farah. 'Then, right at the cusp of [OpenAI's GPT] 3.5 launching, we were like: This is the moment. This is where you can start solving these problems in an authentic way. And that made us immediately jump on it.' Now, about two years after the Uraizees walked away from Meta, Nectar Social is launching out of stealth. The company has raised $10.6 million in combined pre-seed and seed funding, led by GV and True Ventures. BAM Ventures, Charge Ventures, FAB Ventures, Flying Fish Ventures, Mercury Fund, Trust Fund by Sophia Amoruso, and XRC Ventures participated in the round. Nectar's customers include Bobbi Brown's Jones Road Beauty, soda brand Olipop, viral California makeup brand Tower28, and skincare device brand Solawave. (On Instagram alone, this group has a combined more than 1.8 million followers.) GV's bet is that Nectar will become essential to brands looking to compete in the crowded e-commerce space, post-DTC boom. 'Brands are inundated by DMs and comments,' said Frédérique Dame, general partner at GV. 'And they need to convert the customer right away on the spot. When the customer asks a question about the product, they're ready to buy. And Nectar is shrinking the actual funnel to instant purchase.' Nectar's tools include AI 'social copilot' agents that autonomously handle community interactions, real-time data, and revenue attribution metrics that tie DMs, mentions, and comments to purchases. (Nectar said that it's already managed more than 500,000 DMs, comments, and mentions, while reducing customers' average response times to about five minutes for inbound social media queries.) And yes, there's absolutely a Gen Z angle here—Salesforce data suggests that 76% of Gen Z is finding products through social media. 'Social is becoming the go-to place for people to discover a brand, build a record with a brand, interact and close the loop on the brand,' said GV's Dame. 'But the magic of this is that it goes from inside out. They can extend it to your email ecosystem.' Misbah and Farah are five years apart, and though their early years took them from Singapore to Sweden to Ireland, much of their childhood was spent in Northern California, where their parents worked in the telecom industry. Nadeem and Amtul Uraizee, their parents, told Fortune via email that they weren't surprised the sisters decided to start a company together. One thing they emphasized: Misbah and Farah have always had a habit of disagreeing—thoughtfully. As kids, they would debate vigorously across family road trips. 'But the moment one of them ever hit any rough patches, the other would drop everything to help,' Nadeem and Amtul wrote to Fortune. 'That's just who they've always been: each other's biggest critics and biggest champions. Now, seeing them run a company together, it honestly feels like the same relationship playing out on a bigger stage. They still disagree (probably more than ever), but they've learned how to turn those disagreements into something meaningful that they can build together.' And what they're trying to build together is a ubiquitous but invisible engine for, essentially, going viral. Conceptually, going viral is interesting for its odd combination of science and mystery. There are, as Misbah points out, ways to build virality. But when something goes viral, it's ultimately because people care genuinely in some way. Which isn't a one-way street—a brand on social media has to consistently show (at scale) that it cares about its customers. 'The best brands are hyperactive,' said Farah. 'They respond to every single person, and they don't only respond—they proactively encourage it.' See you tomorrow, Allie GarfinkleX: @agarfinksEmail: a deal for the Term Sheet newsletter here. Nina Ajemian curated the deals section of today's newsletter. Subscribe here. This story was originally featured on
Yahoo
2 days ago
- Yahoo
Digital Twin Consortium Launches AI Agent Capabilities Periodic Table to Address Market Confusion
A new framework applies digital twin assessment methodology to the rapidly growing AI agent market BOSTON, MA, June 05, 2025 (GLOBE NEWSWIRE) -- The Digital Twin Consortium® (DTC) today announced the AI Agent Capabilities Periodic Table (AIA CPT), a comprehensive framework and the industry's first standardized approach for evaluating AI agent systems based on actual capabilities. The AIA CPT addresses growing market confusion where systems with vastly different capabilities are labeled agents or agentic AI. The new framework applies the same proven methodology that clarified the digital twin market with the Digital Twin Capabilities Periodic Table (DT CPT). Organizations can use the AIA CPT and DT CPT to evaluate integrated solutions combining digital twins with autonomous agent behavior. "The AI agent market faces the same evaluation challenges that digital twins encountered in their early days," said Dan Isaacs, GM & CTO at DTC. "Organizations struggle to compare vendors fairly and set realistic expectations for AI agent implementations. By applying our established capability-based assessment approach, we can help organizations make informed decisions about AI agent investments." The AIA CPT comprises six main categories: perception and knowledge, cognition and reasoning, learning and adaptation, action and execution, interaction and collaboration, and governance and safety. Each category will encompass a range of capabilities, including concrete assessment criteria with measurable performance thresholds. This will enable objective evaluation regardless of vendor terminology. The technology-agnostic design will work across all AI platforms and implementation approaches. The AIA CPT draws insights into AI agent systems across multiple industries and maturity levels, enabling cross-industry AI agent evaluation. The AIA CPT framework defines four maturity levels, from basic conversational agents to sophisticated Multi-Agent Generative Systems (MAGS): Level 1: Conversational Agents Level 2: Procedural Workflow Agents Level 3: Cognitive Autonomous Agents Level 4: MAGS Together, AIA PT and DT CPT provide the means for a comprehensive assessment of intelligent system ecosystems. Organizations can now, in a standardized manner, align AI agent capabilities with digital twin infrastructure requirements, identify and address capability gaps in integrated systems, design agents that effectively leverage twin data and models, and scale agent and digital twin capabilities independently while maintaining integration. Learn more about DTC's AIA CPT. About Digital Twin Consortium Digital Twin Consortium® (DTC) is Accelerating Digital Twin Innovation™. DTC executes the promise of digital twins and associated technologies by working closely with our members to accelerate the market. We foster development, raise awareness through impactful work products, and drive increased digital twin adoption across industries. DTC is a program of Object Management Group®. For more information, visit Note to editors: Digital Twin Consortium is a registered trademark of OMG. See the listing of all OMG trademarks. All other trademarks are the property of their respective owners. CONTACT: Karen Quatromoni Digital Twin Consortium 978-855-0412 Karen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
